800-845-6913
Tuteur & Associates, LLC | Knowledge is Power.
November 5, 2007
November 2007 Leverkusen, Germany and West Haven, Connecticut, USA. – Following consultation with the German Federal Institute for Drugs and Medical Devices (BfArM), the U.S. Food and Drug Administration (FDA), Health Canada, and other health authorities, Bayer announced today that it has elected to temporarily suspend worldwide marketing of Trasylol® (aprotinin injection) until final results from the Canadian BART trial can be compiled, received and evaluated. The company took this global action following direction from the German BfArM and requests from the FDA and other regulators that Bayer temporarily suspend Trasylol marketing in their respective countries until final BART data were available. The BART study is an independent randomized, controlled trial being conducted in high-risk cardiac surgery patients. Continue reading, ‘11-05-2007 | Bayer Temporarily Suspends Global Trasylol® (aprotinin injection) Marketing.’